Genmab A/S (OTCMKTS:GNMSF) Short Interest Update

Genmab A/S (OTCMKTS:GNMSF) was the recipient of a large drop in short interest during the month of February. As of February 28th, there was short interest totalling 61,100 shares, a drop of 23.5% from the February 13th total of 79,900 shares. Based on an average daily trading volume, of 300 shares, the short-interest ratio is currently 203.7 days. Currently, 0.1% of the shares of the company are short sold.

Genmab A/S Stock Performance

Shares of GNMSF stock traded up $11.07 on Monday, reaching $208.89. The stock had a trading volume of 427 shares, compared to its average volume of 3,166. The stock has a market cap of $13.80 billion, a P/E ratio of 11.92 and a beta of 1.08. Genmab A/S has a 1 year low of $186.61 and a 1 year high of $310.56. The company has a 50 day simple moving average of $211.21 and a 200 day simple moving average of $222.86.

Genmab A/S (OTCMKTS:GNMSF) last announced its earnings results on Wednesday, February 12th. The company reported $5.70 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $5.24. Genmab A/S had a return on equity of 19.75% and a net margin of 36.30%.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.